Sorry, you need to enable JavaScript to visit this website.

Scott Gottlieb, M.D.

Special Partner, New Enterprise Associates, Inc.’s healthcare investment team and Resident Fellow of the American Enterprise Institute. Dr. Gottlieb served as the 23rd Commissioner of the U.S. Food and Drug Administration (FDA) from 2017 to 2019.

Prior to serving as Commissioner, Dr. Gottlieb held several roles in the public and private sectors including serving as Managing Director, T.R. Winston & Company from 2013 to 2017. Dr. Gottlieb was previously the FDA’s Deputy Commissioner for Medical and Scientific Affairs from 2005 to 2007, as well as the senior advisor to the FDA Commissioner from 2003 to 2004.

Dr. Gottlieb is a member of the National Academy of Medicine and is a Contributor to the financial news network, CNBC. Director Illumina, Inc., Director of Aetion, Inc. a private healthcare data technology company and Tempus, a private technology company. Board Member of National Resilience, Inc. Scientific Advisory Board Member of CellCarta. Pfizer Director since 2019. Chair of our Regulatory and Compliance Committee and Member of our Science and Technology Committee.